Search Browse Earnings

Nkarta, Inc.

Nasdaq:NKTX

Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Nkarta, Inc. — SlamSEC

Revenue

$0

FY 2024

Adj. EBITDA

-$125.8M

FY 2024

Net Income

-$117.5M

FY 2024

EPS (Diluted)

-$2.40

FY 2024

Stock Price

$2.50

2026-03-06

52W Range

—

P/E Ratio

-1.0x

Market Cap

$177.6M

Cash

$31.0M

FY 2024

Total Debt

—

Net Cash

$31.0M

FY 2024

Enterprise Value

$146.5M

Debt / EBITDA

0.2x

FY 2024

EV / EBITDA

-1.2x

Employees

—